Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...

LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...

Revenue rose 10% to $3.79 billion, surpassing the average $3.74 billion target from analysts polled by FactSet. Sales of the EYLEA HD more than doubled to $305 million. The medication was approved for ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

A higher-dose formulation of Eylea saw U.S. sales more than double Regeneron Pharmaceuticals Inc.'s stock rose 3% early Tuesday, after the company posted better-than-expected fourth-quarter ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...

Regeneron Pharmaceuticals logged a sharp increase in fourth-quarter revenue amid strong demand for a new formulation of its EYLEA product. The biotechnology company posted fourth-quarter earnings ...